31 results on '"Chahine, Claude"'
Search Results
2. The Evolving Role of Bispecific Antibodies in Diffuse Large B-Cell Lymphoma.
3. Zolbetuximab: a potential breakthrough in the treatment landscape of gastric cancer
4. Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study
5. KRASG12C mutation in metastatic colorectal cancer: a new target
6. LAG-3 Inhibitors: Novel Immune Checkpoint Inhibitors Changing the Landscape of Immunotherapy
7. Futibatinib: paving the way to personalized medicine in intrahepatic cholangiocarcinoma
8. When monoclonal gammopathy‐associated chronic neutrophilic leukemia is a reactive process distinct from a clonal myeloproliferative neoplasm: Lessons from mistakes
9. The CLIP1–LTK fusion: a new oncogenic driver in non-small-cell lung cancer?
10. Mechanisms of Resistance to Antibody-Drug Conjugates.
11. KRASG12C mutation in metastatic colorectal cancer: a new target.
12. Urothelial carcinoma in the era of immune checkpoint inhibitors
13. Chemotherapy-free regimen: a new hope in Philadelphia-positive acute lymphoblastic leukemia
14. Clinical significance of the loss of CD20 antigen on tumor cells in patients with relapsed or refractory follicular lymphoma
15. Bortezomib, Lenalidomide, and Dexamethasone in Elderly Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm
16. Ivosidenib for the treatment of relapsed or refractory acute myeloid leukemia with an IDH1 mutation
17. Repeated courses of low‐dose 2 × 2 Gy radiation therapy in patients with indolent B‐cell non‐Hodgkin lymphomas
18. High‐dose cyclophosphamide for hard‐to‐treat patients with relapsed or refractory B‐cell non‐Hodgkin's lymphoma, a phase II result
19. Complete resolution of obstructive colonic amebic pseudotumor with conservative treatment: A case report and literature review
20. Immunological Cytopenias Induced By Anti-Programmed Cell Death (ligand) 1 Antibodies
21. Outcomes of Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Included in Phase I Clinical Trials
22. Feasibility and Benefit of Molecularly-Informed Enrollment into Early Phase Clinical Trials for Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
23. The Impact of Risk-adapted Treatment Strategy on Outcome of Patients with Acute Myeloid Leukemia Aged ≥ 60 Years after Allogeneic Stem Cell Transplant
24. Immunological Cytopenia Induced by Anti-Programmed Cell Death (Ligand) 1 Antibodies
25. Allogeneic Hematopoietic Stem Cell Transplant in Elderly Patients Using Reduce Intensity Conditioning Regimen: A Single Centre Experience
26. BRAF V600E Targetable Mutation in Relapsed/Refractory Multiple Myeloma (R/R MM) Patients: A High Incidence in R/R MM Detected Using Cell Sorting Screening
27. Repetitive Low-Dose Radiation Therapies As an Alternative Option for Indolent Non-Hodgkin Lymphoma
28. The Impact of Risk-Adapted Treatment Strategy on Outcome of Patients with Acute Myeloid Leukemia Aged ≥ 60 Years after Allogeneic Stem Cell Transplantation
29. Dose-Adjusted Rituximab Mini-CYVE (CYtarabine bolus, VEpeside and dexamethasone) for Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma Not Eligible for High Dose Therapy
30. Characteristics and Outcome Of Acute Myeloid Leukemia Following Breast Cancer: Analysis Of 408 Cases and Controls
31. KRAS G12C mutation in metastatic colorectal cancer: a new target.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.